Literature DB >> 18842378

Occurrence of a USA300 vancomycin-intermediate Staphylococcus aureus.

Jeffrey C Hageman1, Jean Patel, Patrick Franklin, Karen Miscavish, Linda McDougal, David Lonsway, Fazle N Khan.   

Abstract

A vancomycin-intermediate Staphylococcus aureus (VISA) isolated from the blood of a 46-year-old patient with endocarditis was determined to be pulsed-field type USA300, daptomycin nonsusceptible, and positive for the Panton-Valentine leukocidin genes. Development of the VISA phenotype does not appear limited to traditional health care strains of S. aureus.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18842378     DOI： 10.1016/j.diagmicrobio.2008.08.005

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  16 in total

1.  Identification and characterization of the multidrug resistance gene cfr in a Panton-Valentine leukocidin-positive sequence type 8 methicillin-resistant Staphylococcus aureus IVa (USA300) isolate.

Authors:  Anna C Shore; Orla M Brennan; Ralf Ehricht; Stefan Monecke; Stefan Schwarz; Peter Slickers; David C Coleman
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Glycopeptide and daptomycin resistance in community-associated MRSA in the UK.

Authors:  A Kirby; C Edwards; C M Broughton; N J Williams
Journal:  Infection       Date:  2011-04-01       Impact factor: 3.553

Review 3.  Mechanisms of vancomycin resistance in Staphylococcus aureus.

Authors:  Susana Gardete; Alexander Tomasz
Journal:  J Clin Invest       Date:  2014-07-01       Impact factor: 14.808

4.  First report of vancomycin-intermediate resistance in sequence type 72 community genotype methicillin-resistant Staphylococcus aureus.

Authors:  Doo Ryeon Chung; Jin Yang Baek; Hyun Ah Kim; Min Hee Lim; So Hyun Kim; Kwan Soo Ko; Cheol-In Kang; Kyong Ran Peck; Nam Yong Lee; Jae-Hoon Song
Journal:  J Clin Microbiol       Date:  2012-05-02       Impact factor: 5.948

Review 5.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

Review 6.  Community-associated methicillin-resistant Staphylococcus aureus case studies.

Authors:  Madeleine G Sowash; Anne-Catrin Uhlemann
Journal:  Methods Mol Biol       Date:  2014

Review 7.  Evolution of community- and healthcare-associated methicillin-resistant Staphylococcus aureus.

Authors:  Anne-Catrin Uhlemann; Michael Otto; Franklin D Lowy; Frank R DeLeo
Journal:  Infect Genet Evol       Date:  2013-05-03       Impact factor: 3.342

8.  A mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin.

Authors:  Karla D Passalacqua; Sarah W Satola; Emily K Crispell; Timothy D Read
Journal:  Antimicrob Agents Chemother       Date:  2012-07-30       Impact factor: 5.191

9.  Impact of accessory gene regulator (agr) dysfunction on vancomycin pharmacodynamics among Canadian community and health-care associated methicillin-resistant Staphylococcus aureus.

Authors:  Brian T Tsuji; Robert D MacLean; Linda D Dresser; Martin J McGavin; Andrew E Simor
Journal:  Ann Clin Microbiol Antimicrob       Date:  2011-05-20       Impact factor: 3.944

10.  Difference in agr dysfunction and reduced vancomycin susceptibility between MRSA bacteremia involving SCCmec types IV/IVa and I-III.

Authors:  Hee-Chang Jang; Seung-Ji Kang; Su-Mi Choi; Kyung-Hwa Park; Jong-Hee Shin; Hyon E Choy; Sook-In Jung; Hong Bin Kim
Journal:  PLoS One       Date:  2012-11-12       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.